

---

## **Pharmacy Scorecard and DRG Report Card Project Scope and Organization**

**Version 2.0  
Revised 9 July 2008**

### 3. Project Organization

#### 3.1 Project Roles and Responsibilities

The chart below describes the primary responsibilities for each project role, such as executive sponsor, business owner, project manager, customer, and functional manager. Note that project responsibilities are not the same as job responsibilities.

Stakeholder	Project Role	Project Responsibilities
Michael Nnadi Sr. Director Pharmacy	Executive Sponsor	<ul style="list-style-type: none"> <li>- Secures funding</li> <li>- Monitors the project's progress</li> <li>- Provides decision support as needed</li> <li>- Serves as Project Steering committee member</li> <li>- Helps facilitate communication</li> </ul>
John Lang, Manager Pharmacy Clinical Systems  TBA, Pharmacy Systems Analyst	Business Owners	<ul style="list-style-type: none"> <li>- Supports development, review and approval of the Project Charter document</li> <li>- Reviews/Approves the Project Requirements Specification</li> <li>- Reviews/Approves the Project Management Plan</li> <li>- Assists the Project Manager in overcoming organizational obstacles</li> <li>- Advises the Project Manager and discusses the project status with this manager on a regular basis</li> <li>- Provides sign-off of all deliverables requiring approval</li> <li>- Serves as Project Steering committee member</li> </ul>
Rob Phelps, SHS Director of Informatics & Data Warehousing  Dale Less, SHS Program Manager of Analysis & Research  John White, SHS Senior Epidemiologist  Will Bryant, Financial Planning and Analysis Sr. Financial Analyst  Tom Cox, Strategic Sourcing	Subject Matter/ Technical Experts	<ul style="list-style-type: none"> <li>- Provides project requirements</li> <li>- Represents business area interests</li> <li>- Provides business subject matter knowledge/expertise</li> <li>- Provides support for analysis/design, evaluations and final testing</li> </ul>
Sabrina Vereen, SHS Sr. Business Analyst	Project Manager	<ul style="list-style-type: none"> <li>- Prepares Project Management documents</li> <li>- Plans, leads and controls application of organizational resources to project activities</li> </ul>
AmeriSource Bergen Corp.	Vendor Support	<ul style="list-style-type: none"> <li>- Provides access and basic overview of vendor data on pricing, inventory</li> </ul>

## Approval

### Executive Sponsor Approval

Executive Sponsor Name/Title: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

*Note: Executive Sponsor (Executive Director level or above) approval is required for this document.*



# FMC - Pharmacy Initiatives Scorecard: Top Drugs Detail

Nov 11, 2008 3:45:20 PM

	Variable Drug Cost					Drug Cost Per APD					% Change YTD 4Y Prior - 3Y Prior	% Change YTD 2Y Prior - 1Y Prior	% Change YTD 2Y Prior - Year				
	2004	2005	2006	2007	2008	% Change YTD 4Y Prior - 3Y Prior	2004	2005	2006	2007				2008	% Change YTD 3Y Prior - 2Y Prior	% Change YTD 2Y Prior - Year	
<b>ANTIBACTERIALS, MISCELLANEOUS</b>																	
EAPOTAMYCIN 500 MG INJ	\$77,223	\$54,526	\$5,493,923	\$46,154	\$1,453,822	-5.25%	196.34%	120.31%	\$303.53	\$41.00	\$39.46	\$33.90	\$47.83	-0.64%	-4.57%	-11.66%	40.41%
LINEZOLID 200 MG/100 ML INJ				\$419									\$24.66				
LINEZOLID 600 MG/300 ML INJ	\$65,206	\$90,274	\$112,736	\$141,783	\$156,045	36.36%	25.14%	36.71%	\$77.00	\$45.68	\$20.29	\$36.83	\$38.64	-6.05%	-22.77%	33.88%	9.05%
QUINUPRES/DNL-OPRES 500 MG INJ		\$8,481	\$4,482	\$30,796	\$53		80.28%	4,208.15%	\$71.19	\$15.17	\$15.73	\$8.22	\$42.66		-97.03%	5,101.91%	69.66%
<b>ANTIBACTERIALS, MISCELLANEOUS</b>	<b>\$142,521</b>	<b>\$155,730</b>	<b>\$267,136</b>	<b>\$289,194</b>	<b>\$288,770</b>	<b>21.79%</b>	<b>80.15%</b>	<b>-3.11%</b>	<b>\$53.30</b>	<b>\$31.22</b>	<b>\$77.69</b>	<b>\$31.74</b>	<b>\$35.40</b>	<b>-32.66%</b>	<b>-12.44%</b>	<b>23.95%</b>	<b>9.73%</b>
ASACARIBAN 250 MG/2.5 ML INJ	\$38,039	\$87,245	\$7,669	\$146,788	\$64,622	100.81%	-11.45%	109.37%	\$218.61	\$114.82	\$106.09	\$132.95	\$188.67	-59.97%	-10.36%	20.31%	14.89%
EVANEROLIN 250 MG/5 ML INJ	\$281,147	\$138,803	\$250,590	\$186,348	\$169,715	-14.59%	7.73%	12.42%	\$77.69	\$96.43	\$106.39	\$119.24	\$99.60	22.10%	11.96%	12.90%	-17.26%
DALTEPARIN 2500 UNITS INJ		\$121									\$10.08						
ENCORFARIN NA 100MG/ML INJ NOV		\$4,603	\$10,791	\$1,763			290.57%	-63.67%		\$22.55	\$82.61	\$38.32				194.90%	-33.62%
ENCORFARIN 100 MG/1 ML INJ	\$174,546	\$197,054	\$174,723	\$142,842	\$142,842	12.13%	2.11%	-1.62%	\$18.15	\$18.80	\$21.36	\$21.05	\$22.92	1.60%	14.03%	-3.67%	10.31%
ENCORFARIN 120 MG INJ	\$59,364	\$77,464	\$76,469	\$78,272	\$76,469	-3.31%	15.08%	15.08%	\$22.28	\$26.96	\$25.43	\$27.34	\$32.35	14.14%	3.01%	5.29%	19.28%
ENCORFARIN 150 MG INJ	\$39,553	\$56,195	\$55,893	\$44,446	\$43,547	50.29%	5.06%	-13.41%	\$19.35	\$26.72	\$29.23	\$23.47	\$30.44	35.11%	9.04%	-20.49%	29.03%
ENCORFARIN 20 MG/0.2 ML INJ		\$15	\$157				1,071.97%	-7.93%		\$1.32	\$1.32	\$1.32	\$1.32			80.83%	-67.77%
ENCORFARIN 30 MG/0.3 ML INJ	\$130,431	\$183,043	\$150,394	\$130,509	\$250,009	35.27%	40.00%	30.99%	\$9.02	\$9.09	\$8.98	\$9.79	\$9.88	9.44%	-9.51%	8.45%	1.84%
ENCORFARIN 40 MG/0.4 ML INJ	\$99,020	\$72,786	\$712,903	\$715,928	\$653,052	20.54%	0.23%	7.26%	\$5.44	\$10.43	\$9.99	\$10.41	\$10.95	11.07%	-4.88%	4.37%	5.19%
ENCORFARIN 60 MG/0.6 ML INJ	\$137,380	\$132,815	\$100,542	\$105,139	\$64,402	3.50%	-25.39%	1.81%	\$11.76	\$12.93	\$12.37	\$11.85	\$12.24	12.10%	-1.15%	-7.23%	4.77%
ENCORFARIN 80 MG/0.8 ML INJ	\$214,625	\$247,303	\$225,990	\$206,084	\$176,468	12.70%	-8.77%	-10.46%	\$14.40	\$15.90	\$16.57	\$17.87	\$17.48	9.40%	4.14%	5.73%	0.68%
FONDAPARINUX SODIUM 10 MG INJ		\$11,920	\$7,168	\$5,378			-30.55%	-8.61%		\$33.08	\$17.06	\$17.29				-30.71%	17.27%
FONDAPARINUX SODIUM 2.5 MG INJ	\$11,171	\$13,256	\$55,537	\$107,504	\$39,887	11.17%	150.18%	276.22%	\$17.57	\$23.20	\$17.49	\$16.33	\$16.39	40.28%	-26.64%	6.04%	0.87%
FONDAPARINUX SODIUM 5 MG INJ		\$3,994	\$6,720	\$5,109			115.30%	-11.45%		\$15.60	\$12.81	\$13.29				-33.23%	7.11%
FONDAPARINUX SODIUM 7.5 MG INJ		\$15,667	\$21,906				65.94%	1.29%		\$14.30	\$15.41	\$20.39				5.73%	37.45%
<b>ANTICOAGULANTS, MISCELLANEOUS</b>	<b>\$1,678,155</b>	<b>\$1,955,904</b>	<b>\$2,049,218</b>	<b>\$2,150,805</b>	<b>\$1,728,730</b>	<b>15.17%</b>	<b>4.48%</b>	<b>-5.60%</b>	<b>\$13.30</b>	<b>\$14.48</b>	<b>\$13.87</b>	<b>\$4.19</b>	<b>\$4.18</b>	<b>8.23%</b>	<b>-4.07%</b>	<b>2.29%</b>	<b>-1.19%</b>
LENITRACETAP 500MG/5ML INJ		\$14,358	\$81,425	\$51,250			654.37%	45.37%	\$21.75	\$13.22	\$14.09					-66.29%	0.32%
<b>ANTICOAGULANTS, MISCELLANEOUS</b>		<b>\$14,358</b>	<b>\$81,425</b>	<b>\$51,250</b>			<b>654.37%</b>	<b>45.37%</b>		<b>\$21.76</b>	<b>\$13.22</b>	<b>\$14.09</b>				<b>-66.29%</b>	<b>0.32%</b>
ZORIEDONIDE 200MG/2ML INJ	\$397,263	\$400,013	\$322,398	\$364,325	\$389,616	0.77%	-20.85%	11.75%	\$31.90	\$27.85	\$21.92	\$26.09	\$32.66	-16.35%	-20.73%	17.55%	27.70%
ZORIEDONIDE 12.5 MG CR TAB		\$2,122	\$3,106	\$2,789			66.46%	6.09%		\$1.33	\$1.28	\$1.46				-3.91%	14.17%
ZORIEDONIDE 12.5 MG CR TAB		\$209	\$244	\$209			258.15%	6.18%		\$0.91	\$1.10	\$1.47				14.57%	30.26%

**Pharmacy Report: DRG Report Card**  
**Congestive Heart Failure**  
 Revised August 8, 2008

**Table 1. Demographics**

<b>Demographic Characteristics</b> (N=296 patients/325 discharges with CHF Diagnoses from January 1, 2008 through March 31, 2008 at FMC)				
	<b>Count</b>		<b>Frequency</b>	
<b>Gender</b>				
Female	161		54.4%	
Male	135		45.6%	
<b>Race</b>				
Caucasian	228		77.0%	
African American	67		22.6%	
Asian	1		0.3%	
<b>Death Indicator</b>				
No	282		95.3%	
Yes	14		4.7%	
<b>At Least One Readmission within 30 Days (n=296) (for any reason)</b>				
No	206		69.6%	
Yes	90		30.4%	
<b>Ever Seen in a HF Clinic</b>				
No	253		85.5%	
Yes	43		14.5%	
<b>Patient's PCP is an IPOF (based on all discharges)</b>				
No	108		33.2%	
Yes	217		66.8%	
<b>Discharge Disposition (based on all discharges)</b>				
Routine Discharge	179		55.1%	
Home Care	78		24.0%	
Long Term Care	41		12.6%	
Expired	14		4.3%	
Hospice	10		3.1%	
Correctional Facility	2		0.6%	
Short Term Hospital	1		0.3%	
<b>Admission Source (based on all discharges)</b>				
Emergency Unit	284		87.4%	
Unscheduled Admission	33		10.2%	
Scheduled Admission	5		1.5%	
Other	3		0.9%	
<b>Payer (based on all discharges) N=325</b>				
Medicare Inpatient	169		52.0%	
Medicare - Managed Care	112		34.5%	
BCBS	15		4.6%	
Medicaid	11		3.4%	
Self Pay / Indigent Care	2		0.6%	
Other	16		4.9%	
<b>N=325 admissions</b>	<b>ED Admission (N=284)</b>		<b>Non-ED Admission (N=41)</b>	
<b>Ever Seen in a HF Clinic (chi square p=0.0004)</b>	Num	%	Num	%
No (n=275 admissions)	248	90.2%	27	9.8%
Yes (n=50 admissions)	36	72.0%	14	28.0%
Of those patients previously seen in a Heart Failure clinic, 72% were admitted through the Emergency Department, compared to 90.2% of those patients never seen in a Heart Failure clinic.				
<b>N=296 patients</b>	<b>No Readmissions within 30 (N=206)</b>		<b>Readmissions within 30 days (N=90)</b>	
<b>Ever Seen in a HF Clinic (Fishers Exact test p=0.0772)</b>	Num	%	Num	%
No (n=253 patients)	179	70.8%	74	29.2%
Yes (n=43 patients)	27	62.8%	16	37.2%
Of those patients previously seen in a Heart Failure clinic, 37.2% had at least two HF-related admissions during the 1 <sup>st</sup> quarter of 2008, compared to 29.2% of those patients never seen in a Heart Failure clinic.				

**Pharmacy Report: DRG Report Card**  
**Congestive Heart Failure**  
 Revised August 8, 2008

**Table 3. Pharmacy Characteristics-continued**

<b>Pharmacy Characteristics</b>		
<b>Drug General Therapeutic Class (all meds; all discharges) n=12,675</b>		
Diuretics	1376	10.9%
Electrolyte/Caloric/H2O	1326	10.5%
Gastrointestinal	1315	10.4%
Analgesics	1272	10.0%
Cardiovascular	1161	9.2%
Anti-Asthmatics	1025	8.1%
Blood	818	6.5%
Cardiac Drugs	812	6.4%
Hypoglycemic	788	6.2%
Psychotherapeutic Drugs	445	3.5%
Autonomic Drugs	336	2.7%
Sedative/Hypnotics	301	2.4%
Hormones	265	2.1%
Anti-Histamines	239	1.9%
Anti-Infectives	206	1.6%
Cough/Cold Preparations	173	1.4%
Unclassified Drug Products	142	1.1%
CNS Drugs	104	0.8%
EENT Preps	107	0.8%
Anti-Arthritics	76	0.6%
Anesthetics	75	0.6%
Thyroid Preps	80	0.6%
Vitamins	79	0.6%
Skin Preps	50	0.4%
Biologicals	26	0.2%
Anti-Parkinson Drugs	17	0.1%
Muscle Relaxant	10	0.1%
Pre-Natal Vitamins	13	0.1%
Smoking Deterrents	13	0.1%
Diagnostic	15	0.1%
Anti-Neoplastics	3	0.0%
Immunosuppressant	4	0.0%
Antidotes	3	0.0%
<b>DEA Code (all meds; all discharges)</b>		
0	11637	90.9%
2	250	2.0%
3	134	1.0%
4 or 5	779	6.1%

**Table 3. Pharmacy Characteristics – continued**

<b>Pharmacy Characteristics</b>		
<b>Drug Class (all meds; all discharges) n=12,675</b>		
Antacids	227	1.8%
Anti-Anxiety Agents	268	2.1%
Attention Deficit Disorder	2	0.0%
Diagnostics	18	0.1%
Hemolytics	76	0.6%
Insulin	671	5.3%
Laxative	581	4.6%
Smoking Deterrents	13	0.1%
Vitamins	57	0.4%
Unspecified	10,762	84.9%

**Pharmacy Report: DRG Report Card**  
**Congestive Heart Failure**  
 Revised August 8, 2008

**Table 5a. Sequencing**

<b>Sequencing Characteristics (n=325)</b>		
<b>First Drug Ordered Upon Admission</b> (*mean time from admit to pharmacy order of meds 2.7 ± 2.4 hours; mean time from admit to start of meds 4.9 ± 14.0 hours)		
Anti-Asthmatics (*mean time=2.6 hrs; 2.8 hrs)	55	16.9%
Sedative/Hypnotics (*mean time=2.2 hrs; 2.2 hrs)	49	15.1%
<b>Cardiovascular</b> (*mean time=2.1 hrs; 2.6 hrs)	33	10.2%
<b>Diuretics</b> (*mean time=2.7 hrs; 5.0 hrs)	31	9.5%
Gastrointestinal (*mean time=2.8 hrs; 3.4 hrs)	29	8.9%
Hypoglycemic (*mean time=2.8 hrs; 9.6 hrs)	24	7.4%
<b>Blood</b> (*mean time=2.8 hrs; 4.5 hrs)	21	6.5%
Electrolyte/Caloric/H2O (*mean time=3.2 hrs; 3.4 hrs)	19	5.8%
Analgesics (*mean time=3.9 hrs; 9.9 hrs)	14	4.3%
<b>Cardiac Drugs</b> (*mean time=2.5 hrs; 4.4 hrs)	14	4.3%
Psychotherapeutic Drugs (*mean time=3.4 hrs; 4.5 hrs)	9	2.8%
Vitamins (*mean time =1.8 hrs; 47.5 hrs)	5	1.5%
Anti-Arthritics (*mean time =3.6 hrs; 7.9 hrs)	3	0.9%
Anti-Histamines (*mean time =5.8 hrs; 5.8 hrs)	3	0.9%
Anti-Infectives	4	1.2%
<b>Autonomic Drugs</b> (*mean time =2.9 hrs; 5.2 hrs)	3	0.9%
EENT Preps (*mean time =3.0 hrs; 9.9 hrs)	2	0.6%
Smoking Deterrents	2	0.6%
CNS Drugs	1	0.3%
Cough/Cold Preparations	1	0.3%
Hormones	1	0.3%
Thyroid Preps	1	0.3%
Unclassified Drug Products (*mean time =3.9hrs; 3.9 hrs)	1	0.3%

**Table 5b. Sequencing**

<b>Sequencing Characteristics (n=325 discharges)</b>		
<b>Second Drug Ordered Upon Admission</b> (mean time from admit to pharmacy order of meds 2.9 ± 2.2 hours; mean time from admit to start of meds 4.3 ± 4.4 hours)		
Gastrointestinal (*mean time =2.2 hrs; 2.7 hrs)	69	21.2%
Anti-Asthmatics (*mean time =3.0 hrs; 3.4 hrs)	45	13.8%
<b>Cardiovascular</b> (*mean time =3.3 hrs; 4.3 hrs)	41	12.6%
<b>Blood</b> (*mean time =2.9 hrs; 3.2 hrs)	24	7.4%
<b>Diuretics</b> (*mean time =2.9 hrs; 6.0 hrs)	23	7.1%
Sedative/Hypnotics (*mean time =2.3 hrs; 2.3 hrs)	23	7.1%
Analgesics (*mean time =3.1 hrs; 5.6 hrs)	20	6.2%
Hypoglycemic (*mean time =3.1 hrs; 12.8 hrs)	15	4.6%
Psychotherapeutic Drugs (*mean time =2.9 hrs; 3.7 hrs)	15	4.6%
Electrolyte/Caloric/H2O (*mean time =3.1 hrs; 5.0 hrs)	14	4.3%
<b>Cardiac Drugs</b> (*mean time =2.2 hrs; 4.4 hrs)	12	3.7%
Anti-Histamines (*mean time =4.5 hrs; 4.5 hrs)	4	1.2%
Hormones (*mean time =3.5 hrs; 4.0 hrs)	4	1.2%
Anesthetics (*mean time =1.3 hrs; 1.3 hrs)	3	0.9%
CNS Drugs (*mean time =3.3 hrs; 7.2 hrs)	3	0.9%
Unclassified Drug Products	3	0.9%
Anti-Infectives	2	0.6%
EENT Preps	2	0.6%
Anti-Arthritics (*mean time =1.8 hrs; 7.9 hrs)	1	0.3%
<b>Antidotes</b>	1	0.3%
Autonomic Drugs	1	0.3%

**Pharmacy Report: DRG Report Card**

Congestive Heart Failure

Revised August 8, 2008

**Table 7– Most Expensive Drugs by General Therapeutic Class – Prescription Drugs Only**

Most Expensive Brand Drugs Used			Most Expensive Generic Drugs Used		
<b>Analgesic</b>			<b>Analgesics</b>		
Oxycontin	MS Contin (Morphine)	Demerol	Methadone	Fentanyl	Butorphanol
<b>Anesthetic</b>			<b>Anesthetic</b>		
Diprivan	Xylocaine Jelly	Sensorcaine	Lidocaine		
<b>Anti-Arthritic</b>			<b>Anti-Arthritic</b>		
Enbrel	Mobic	Cerebrex	Indomethacin		
<b>Anti-Asthmatic (&gt;\$80/unit)</b>			<b>Anti-Asthmatic</b>		
Advair	Combivent Inh	Atrovent Inh	Acetylcysteine	Albuterol	
<b>Anti-Histamine (\$76/unit)</b>			<b>Anti-Histamine</b>		
Optivar 0.05% Solution			Diphenhydramine		
<b>Anti-Infective</b>			<b>Anti-Infective</b>		
Zyvox	Levaquin	Cefzil	Fluconazole	Azithromycin	Vancomycin
<b>Anti-Neoplastics</b>			<b>Anti-Neoplastics</b>		
Casodex	Hydrea		Tamoxifen		
<b>Anti-Parkinson</b>			<b>Anti-Parkinson</b>		
Comtan	Requip	Mirapex	Carbidopa/Levodopa	Amantadine	
<b>Autonomics</b>			<b>Autonomics</b>		
Aricept	Razadyne	Inderal	Phentolamine	Norepinephrine	Metoprolol
<b>Biologicals</b>			<b>Biologicals</b>		
Pneumovax		Fluzone	Not Applicable		
<b>Blood (Aranesp between \$652-\$869/unit)</b>			<b>Blood</b>		
Aranesp	Integrilin	Lovenox	Argatroban	HETASTARCH	Heparin
Activase	Thrombin JMI	Arixtra			
<b>Cardiac Drugs</b>			<b>Cardiac Drugs (Amiodarone &gt; \$151)</b>		
Corvert	Nitrol Ointment	Tambacor	Amiodarone	Adenosine	Diltiazem
<b>Cardiovascular</b>			<b>Cardiovascular</b>		
Catapres	Revatio	Nipride	Hydralazine	Labetalol	Simvastatin
Lipitor	Pravachol	Tricor			
<b>CNS Drugs</b>			<b>CNS Drugs</b>		
Namenda	Depakote	Keppra	Clonazepam	Phenytoin	
<b>Diagnostic (between \$131-\$196/unit)</b>			<b>Diagnostic</b>		
Adenoscan			Not Applicable		
<b>Diuretics</b>			<b>Diuretics</b>		
Edecrin	Demadex	Diamox	Acetazolamide	Bumetanide	Torsemide
<b>ENT Preps (&gt;\$75/unit)</b>			<b>ENT Preps</b>		
Cosopt	Rhinocort	Nasacort	Prednisolone	Fluticasone	Fluorometholone
<b>Electrolyte/Minerals</b>			<b>Electrolyte/Minerals</b>		
Repliva	Kayexalate		Sodium Polystyrene	Dextrose	
<b>Gastrointestinal</b>			<b>Gastrointestinal</b>		
Nexium	Golytely	Protonix	Polyethylene Glycol	Sucrafate	
<b>Hormones (&gt;\$75/unit)</b>			<b>Hormones</b>		
Flovent	Premarin	Pulmicort	Vasopressin	Dexamethasone	Prednisone
<b>Hypoglycemics – Insulin (&gt;\$44/unit)</b>			<b>Hypoglycemics</b>		
Lantus	Humalog	Novolog	Glipizide	Glimepiride	Metformin
<b>Psychotherapeutic Drugs</b>			<b>Psychotherapeutic Drugs</b>		
Ativan	Abilify	Geodon	Haloperidol	Diazepam	Venlafaxine

Red/Bold = Cost per unit > \$10

**Pharmacy Report: DRG Report Card**  
**Congestive Heart Failure**  
 Revised August 8, 2008

**Table 8– Continuous Variables – Stratified by Select Covariates - continued**

<b>By 30 Day Readmission (n=296)</b>	<b>No Mean (SD) Median n=206</b>	<b>Yes Mean (SD) Median n=90</b>
Age at Discharge (n=296) yrs	75.0 (13.1) 77.0	74.4 (14.5) 78.5
Length of Stay (n=325 discharges) days	6.0 (4.1) 5.0	7.8 (7.9) 6.0
Charlson Comorbidity Index (n=325) (Mann Whitley p=0.0018)	5.2 (2.5) 5.0	6.2 (2.8) 6.0
<b>Num of Unique Rx Meds During LOS (n=325)</b>		
<b>Average Aggregate Rx Drug Cost<sup>6</sup> per Admission</b>	\$181.73 (233.65) 94.01	\$213.04 (340.16) 114.04
Average Cost of Rx Generic drugs (n=325)	\$12.03 (23.16) 6.26	\$13.69 (23.86) 6.42
Average Cost of Rx Brand drugs (n=324)	\$170.52 (227.49) 86.94	\$199.35 (322.34) 107.17
Percent Rx Brand Cost/All Rx Cost (n=324)	85.1 (20.5) 92.9	87.7 (16.9) 93.0
Total Cost (n=325)	\$7,871 (6,570) 6,014	\$10,596 (16,235) 6,260
Total Reimbursement (n=319)	\$7,358 (5,070) 5,974	\$10,751 (36,829) 5,965
Estimated Profit (n=319)	-\$547 (5,423) -21	\$571 (24,228) -125
<b>By IPOF status (n=325)</b>	<b>No Mean (SD) Median n=108</b>	<b>Yes Mean (SD) Median n=217</b>
Age at Discharge (n=296) yrs (Mann Whitley p=0.0007)	71.6 (13.2) 73.0	76.4 (13.4) 80.0
Length of Stay (n=325) days (Mann Whitley p=0.1104)	7.5 (7.2) 6.0	6.2 (4.9) 5.0
Charlson Comorbidity Index (n=325)	5.3 (2.8) 5.0	5.7 (2.6) 5.0
Num of Unique Rx Meds During LOS (n=325)	19.7 (8.2) 18.0	18.8 (5.8) 18.0
<b>Average Aggregate Rx Drug Cost<sup>6</sup> per Admission</b>	\$205.57 (328.17) 102.94	\$186.61 (247.07) 102.79
Average Cost of Rx Generic drugs (n=325) (Mann Whitley p=0.0004)	\$19.82 (37.49) 7.83	\$9.04 (9.24) 5.32
Average Cost of Rx Brand drugs (n=324)	\$187.48 (302.93) 93.32	\$177.56 (245.22) 93.15
Percent Rx Brand Cost/All Rx Cost (n=324) (Mann Whitley p=0.0002)	81.5 (21.7) 90.0	88.3 (17.6) 93.9
Total Cost (n=325) (Mann Whitley p=0.0073)	\$11,479 (16,578) 7,560	\$7,532 (6,568) 5,731
Total Reimbursement (n=319) (Mann Whitley p=0.0369)	\$12,733 (38,284) 5,977	\$6,483 (25,355) 5,965
Estimated Profit (n=319)	\$1,132 (25,108) -774	-\$790 (50,533) 386
<b>By LOS &gt;10 days (n=325)</b>	<b>No Mean (SD) Median n=276</b>	<b>Yes Mean (SD) Median n=49</b>
Age at Discharge (n=296) yrs	74.7 (14.0) 78.0	75.8 (10.7) 77.0
Charlson Comorbidity Index (Mann Whitley p=0.0010)	5.4 (2.6) 5.0	6.2 (2.9) 6.0
Num of Unique Rx Meds During LOS (n=325) (Mann Whitley p<0.0001)	17.9 (5.1) 17.0	25.8 (9.9) 24.0
<b>Average Aggregate Rx Drug Cost<sup>6</sup> per Admission</b> (Mann Whitley p<0.0001)	\$158.72 (197.55) 96.42	\$385.48 (497.15) 212.37
Average Cost of Rx Generic drugs (n=325) (Mann Whitley p<0.0001)	\$8.51 (9.86) 5.17	\$35.79 (49.90) 23.60
Average Cost of Rx Brand drugs (n=324) (Mann Whitley p=0.0010)	\$150.76 (196.54) 87.24	\$349.69 (467.54) 185.48
Percent Rx Brand Cost/All Rx Cost (n=324) (Mann Whitley p=0.0699)	86.4 (20.0) 93.5	84.2 (14.4) 89.0
Total Cost (n=325) (Mann Whitley p<0.0001)	\$6,105 (3,353) 5,466	\$24,272 (21,890) 17,080
Total Reimbursement (n=319) (Mann Whitley p<0.0001)	\$6,672 (3,406) 5,919	\$19,217 (56,205) 7,293
Estimated Profit (n=319) (Mann Whitley p<0.0001)	\$578 (3,673) 662	-\$4,271 (37,831) -8,973